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Abstract
Background: Sepsis leads to high mortality, therefore risk stratification is important. The abbMEDS (abbreviated
Mortality Emergency Department Sepsis) score assesses sepsis severity and predicts mortality. In community-acquired
pneumonia, the CURB-65 (Confusion, Urea, Respiration, Blood pressure, Age) also provides support in clinical decisions
regarding antibiotic treatment and clinical disposition.
We investigated the predictive value and feasibility of the abbMEDS and CURB-65 in sepsis patients at the ED and the
relationship between the scores and antibiotic treatment and clinical disposition (i.e. admission and type of ward).
Methods: In this retrospective cohort study, we included 725 sepsis patients at the ED. We investigated the value in
predicting 28-day mortality and feasibility of both scores. We calibrated the abbMEDS. We further assessed the
relationship between the three risk categories per score and antibiotic treatment (i.e. oral and intravenous narrow or
broad-spectrum) and clinical disposition.
Results: Both abbMEDS and CURB-65 were good predictors of 28-day mortality (13.0 %) (AUC 0.77 [95 % CI 0.72 – 0.83]
and 0.73 [95 % CI 0.67 - 0.78], respectively) and feasible (complete score 92.7 and 93.9 %, respectively). In the high risk
category of the abbMEDS, all patients were admitted and treated with intravenous broad-spectrum antibiotics. In the
high risk category of the CURB-65, 2.5 % were not admitted and 4.4 % received no antibiotics.
Conclusion: Both abbMEDS and CURB-65 are good predictors of 28-day mortality in septic ED patients. The abbMEDS
is well calibrated and matches current clinical decisions concerning antibiotic treatment and clinical disposition, while
this is less so for the CURB-65. In the future, use of the abbMEDS at the ED may improve sepsis care when its value as a
decision support tool can be confirmed.
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Background
Sepsis, which is defined as a systemic inflammatory re-
sponse syndrome (SIRS) to an infection, is a broad clinical
entity and a deadly disease [1, 2]. Sepsis can be classified as
sepsis, severe sepsis or septic shock, which are associated
with an increasing in-hospital mortality of16 % (sepsis) to
46 % (septic shock) [1–3]. Therefore, sepsis is an important
cause of death and puts significant strain on healthcare
budgets [4].
Risk stratification tools aim to assess severity of illness.
In patients with community-acquired pneumonia (CAP),
the CURB-65 score (Confusion, Urea, Respiration, Blood
pressure, Age > 65 years) stratifies patients into three risk
categories (low, intermediate, high) that predict 28-day
mortality well [5]. When applied to patients with suspected
infection from all foci (including CAP), the CURB-65 had
good discriminatory value with regard to 28-day in-hospital
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mortality [6]. Besides prediction of mortality for patients
with CAP, the CURB-65 provides decision support for the
physician, as it advises on two management decisions,
namely choice of antibiotics (e.g. small or broad-spectrum)
and clinical disposition (i.e. whether a patient should be ad-
mitted to the hospital and to what type of ward) [7, 8]. The
CURB-65 can therefore (in patients with CAP) be used as a
decision support tool in addition to the use as an estimator
of mortality risk. For patients with sepsis, the abbMEDS
(Abbreviated Mortality in Emergency Department Sepsis)
score, derived from the MEDS (Mortality in Emergency
Department Sepsis) score has good predictive value con-
cerning 28-day mortality [9, 10]. It would be ideal, however,
if the abbMEDS could provide the same clinical guidance
for sepsis as the CURB-65 does for CAP. Since there is an
overlap between sepsis and CAP, we hypothesize that both
the abbMEDS and CURB-65 risk categories can be related
to decisions concerning management in sepsis patients.
The aim of our study was to investigate the predictive
value and feasibility of the abbMEDS and CURB-65 in in-
ternal medicine patients presenting with sepsis at the ED.
In addition, we aimed to assess the relationship between
the three risk categories defined by both scores and two
clinical decisions, i.e. empirical antibiotic treatment and
clinical disposition.
Methods
Study design and setting
We performed a retrospective study of a cohort of patients.
The Maastricht University Medical Centre (MUMC+) is a
secondary and tertiary care university hospital in The
Netherlands with a capacity of 715 beds. There are 30,235
ED visits per year; approximately 5000 patients are assessed
by an internist. Most patients are referred by a general
practitioner before visiting the ED [11]. This study was
approved by the Medical Ethics Committee of MUMC+,
and informed consent was deemed not to be necessary.
Selection of participants
We reviewed the ED charts of all patients who visited
the ED between 1 April 2011 and 1 August 2012 and
who were assessed by an internist. Part of these patients
(n = 704; 81.2 %) have been included in another study in
which we investigated which sepsis patients were trans-
ported by ambulance [12]. We included patients above
18 years of age, who had two or more SIRS criteria and
either suspected or proven infection (i.e. who fulfilled the
criteria for sepsis, severe sepsis or septic shock) [1, 3].
Patients were excluded if the current admission was a re-
admission within the study period (n = 108, 12.5 %), or
when data on 28-day mortality could not be retrieved
(n = 21, 2.4 %), despite contacting the general practitioner.
Furthermore, patients were excluded when the ED chart
was not complete (n = 7, 0.8 %) or when the patient died at
the ED before the chart was completed (n = 1, 0.1 %).
Methods and measurements
All data were retrieved from the ED charts and the
hospital’s electronic database by the use of standard-
ized forms and by two independent researchers. We
recorded date of birth, sex, comorbidity, vital signs,
laboratory results, suspected focus of infection, items
of the abbMEDS and CURB-65 score (Additional file 1:
Table S1), antibiotic treatment, results of microbiology
cultures, clinical disposition (admission and type of ward),
length of hospital stay and 28-day mortality.
Since the respiratory rate and Glasgow Coma Scale
were not always exactly documented in the ED charts,
we derived these items from other information in the
chart in the same way as others did [6]. Items of the
abbMEDS and CURB-65 were derived from patient charts.
The abbMEDS and CURB-65 score were calculated and
patients were assigned to the three defined risk categories
(low, intermediate, high) of each score (Additional file 1:
Table S1) [5, 9]. To assess the discriminatory value of both
scores in the daily practice of a busy ED, only complete
scores were included in our analysis with the exception of
the missing abbMEDS item ‘nursing home resident’, which
we imputed. This item could not always be scored (n = 113,
15.6 %) and we therefore made the assumption that all
patients under 65 years of age (n = 68, 9.4 %) were not
nursing home residents, unless stated otherwise. Suspected
focus of infection was determined by the treating physician
at the ED.
Antibiotic treatment was categorized into four
groups: no antibiotics, oral antibiotics, intravenous (IV)
narrow-spectrum, or IV broad-spectrum (Additional
file 2: Table S2). When a patient received two narrow-
spectrum antibiotics, which covered both gram positive
and gram negative bacteria, we classified this as IV broad-
spectrum antibiotics. Results of microbiological cultures
were recorded per site (blood, urine, skin/wound and spu-
tum). To minimize the chance of confusing infections
present at the ED with nosocomial infections, we only
recorded results of cultures taken at the day of presentation
and two subsequent days [13, 14].
With regard to the adequacy of current empirical anti-
biotic treatment, we classified the choice of antibiotics
started at the ED as adequate when the identified microor-
ganisms were susceptible for the antibiotics in vitro. If a
patient had a positive culture, but received no antibiotics,
treatment was considered inadequate. When multiple
micro-organisms were cultured, all had to be susceptible
for the administered antibiotics. As coagulase-negative
staphylococci in blood cultures can result from contamin-
ation, discharge letters were checked to retrieve whether
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the treating physician(s) regarded the culture as relevant
or as contamination.
Regarding clinical disposition, all patients were stratified
into three groups: no admission, admission to regular
ward and medium/intensive care unit (MCU/ICU).
Outcomes
To assess the discriminatory value of the abbMEDS and
CURB-65 in predicting 28-day mortality, we plotted
Receiver Operation Characteristic (ROC) curves and
calculated the Area Under the Curve (AUC) with 95 %
confidence intervals (CI). To calibrate the abbMEDS,
we compared the observed data on 28-day mortality
per risk category with those found in the derivation
study of Vorwerk et al. [9]. Since the CURB-65 has only
been derived in CAP patients, we did not calibrate the
CURB-65 in our sepsis cohort. To assess the feasibility
of the abbMEDS and CURB-65, we calculated the total
number and proportion of complete scores in our study
population.
We investigated two clinical decisions, i.e. the choice
regarding empirical antibiotic treatment and the choice
regarding clinical disposition in relation to the three abb-
MEDS and CURB-65 risk categories. As current empirical
antibiotic treatment and clinical disposition might not be
optimal, we assessed 28-day mortality for each of the
groups to check for differences in mortality. To further
evaluate antibiotic treatment, we investigated its adequacy
in the subset of patients with positive cultures. Again,
mortality was calculated for the groups with adequate and
inadequate treatment.
Analysis
We performed all statistical analyses with SPSS v.20.0
(IBM SPSS Statistics, Chicago, Illinois, USA, 2011) and
MedCalc v13.3 (MedCalc Software bvba, Ostend, Belgium,
2014). Continuous data were reported as means and
standard deviations or medians with interquartile ranges,
categorical data as absolute counts and percentages. All
percentages were valid percentages. We used the DeLong
test to compare AUC values [15]. Chi-square or Fisher’s
exact tests were used to test for differences in proportions.
The Mann–Whitney-U test was used to compare medians,
one way ANOVA was used to analyze trends. We analyzed
mortality between the different groups of antibiotic treat-
ment and clinical disposition with Kaplan-Meier survival
analysis and the Log rank test. Associations or differences
were considered statistically significant if p < 0.05.
Results
Patients
In the 15 month study period, 6937 patients were assessed
by an internist at the ED. Of these, 862 had sepsis. We ex-
cluded 137 to form a final cohort of 725 patients (Fig. 1).
In our patients, the prevalence of comorbidity was high,
as 31.3 % had a malignancy and 37.5 % cardiopulmonary
disease (Table 1). Ninety-four patients (13.0 %) died within
28 days after presentation. The median age was higher in
non-survivors than in survivors (73.5 vs. 64.0 years, p <
0.0001). The abbMEDS and CURB-65 scores were higher
in non-survivors than in survivors as well (p < 0.0001).
Discriminatory value
Mortality increased per increasing risk category for both
scores (Fig. 2). Compared to the abbMEDS, the CURB-65
assigned more patients to the high risk category (5.8 vs.
23.3 %). The AUC of the abbMEDS was 0.77 [95 % CI:
0.72–0.83] and that of the CURB-65 0.73 [95 % CI: 0.67–
0.78] for predicting 28-day mortality. This difference was
not statistically significant (p = 0.08).
Feasibility
Complete risk scores could be calculated in 672 (92.7 %)
patients for the abbMEDS, and in 681 (93.9 %) for the
CURB-65 (p = 0.40). The abbMEDS was incomplete due to
missing information concerning the item “nursing home
resident” (n = 45, 6.2 % (>65 years)) or missing thrombo-
cytes (n = 8, 1.1 %). The CURB-65 score was incomplete
mostly due to missing urea values (n = 42, 5.8 %). The
survival of those with complete and incomplete scores was
not different (p = 0.42).
Calibration
Table 2 shows that mortality increased per increasing
abbMEDS risk category in parallel with the mortality
found in the derivation study by Vorwerk et al. [9]. In
our study, mortality in the low risk category was higher
than in the derivation study (3.6 vs. 1.6 %), while in the
intermediate and high risk categories our mortality was
lower (19.5 vs. 23.4 % and 46.2 vs. 59.0 %, respectively).
Antibiotic treatment in relation to risk categories
Of the 725 patients, 78 (10.8 %) did not receive anti-
biotic treatment, 71 (9.8 %) received oral and 34 (4.7 %)
Fig. 1 Flowchart of study population
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IV narrow-spectrum antibiotics and the majority were
treated with IV broad-spectrum antibiotics (74.7 %,
Table 3). In the low and intermediate risk categories of
both scores, antibiotic treatment was almost similar. In
contrast, all high risk abbMEDS patients were treated
with IV broad-spectrum antibiotics, while 15 (9.4 %)
high risk CURB-65 patients were treated with no, oral or
IV narrow-spectrum antibiotics. There were no signifi-
cant differences in mortality between the four groups of
antibiotic treatment in the intermediate risk category of
both scores, but the numbers were too small to draw firm
conclusions. Mortality in the four groups of antibiotic
treatment in the low and high risk categories were not
compared with each other, because in some subgroups
nobody died.
Adequacy of empirical antibiotic treatment in relation to
risk categories
One or more positive culture(s) were found in 244
patients (Additional file 3: Table S3). Seventeen patients
were excluded because their cultures were considered
to result from contamination. Empirical antibiotic treat-
ment was considered adequate in 169 (74.4 %) of the
remaining 227 patients (Table 4). There was no signifi-
cant difference in 28-day mortality between the groups with
adequate (13.6 %) and inadequate treatment (12.1 %, p =
0.48, Log rank test). The higher the abbMEDS risk category,
the more frequent antibiotic treatment was considered
adequate (p = 0.04). For the CURB-65, adequacy of anti-
biotic treatment was not different between the three risk
categories (p = 0.09).
Table 1 Patient characteristics and management
n (%) or median (IQR) All patients Survivors Non-survivors
n = 725 n = 631 (87.0) n = 94 (13.0)
Age, years 65.0 (53.0-77.0) 64.0 (51.0-76.0) 73.5 (63.8-83.0)*
Age >65 351 (48.4) 284 (45.0) 67 (71.3)*
Male sex 338 (46.6) 299 (47.4) 39 (41.5)
Comorbidity
Cancer 292 (40.3) 247 (39.1) 45 (47.9)
Cardiopulmonary 233 (32.1) 189 (30.0) 44 (46.8)*
Immuno compromised 198 (27.3) 175 (27.7) 23 (24.5)
Neuropsychiatric 177 (24.4) 149 (23.6) 28 (29.8)
Diabetes mellitus 134 (18.5) 110 (17.4) 24 (25.5)
Renal disease 96 (13.2) 83 (13.2) 13 (13.8)
Liver disease 22 (3.0) 21 (3.3) 1 (1.1)
Suspected focus of infection
Lower respiratory tract 213 (29.4) 179 (28.4) 34 (36.2)
Urinary tract 152 (21.0) 138 (21.9) 14 (14.9)
Gastrointestinal tract 94 (13.0) 82 (13.0) 12 (12.8)
Hepatobiliary system 43 (5.9) 37 (5.9) 6 (6.4)
Skin 39 (5.4) 34 (5.4) 5 (5.3)
Upper respiratory tract 37 (5.1) 36 (5.7) 1 (1.1)
Other 147 (20.3) 125 (19.8) 22 (23.4)
Antibiotics at ED 647 (89.2) 558 (88.4) 89 (94.7)
Disposition
No admission 63 (8.7) 62 (9.8) 1 (1.1)†
Regular ward 626 (86.3) 544 (86.2) 82 (87.2)
MCU/ICU 36 (5.0) 25 (4.0) 11 (11.7)‡
Length of hospital stay, days 6 (3–11) 7 (3–12) 5 (2–10)‡
Severity scores
AbbMEDS 5 (2–8) 3 (2–7) 8 (6–11)*
CURB-65 1 (0–2) 1 (0–2) 2 (1–3)*
SD Standard Deviation, MCU Medium Care Unit, ICU Intensive Care Unit, IQR Interquartile Range
*P < 0.0001, †P < 0.01, ‡P < 0.05
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Clinical disposition in relation to risk categories
Across the three risk categories of both scores, the majority
of patients were admitted to the hospital (Table 5). The
main difference between both scores was that all high risk
abbMEDS patients were admitted, while four (2.5 %) high
risk CURB-65 patients were not admitted. The proportion
of patients, who were treated as outpatients, was highest in
the low risk category and almost equal for both the
abbMEDS and CURB-65. The only patient in the inter-
mediate risk category of the abbMEDS who was treated
as an outpatient, had terminal cancer and went home on
his own request, where he died. None of the CURB-65
patients, treated as outpatients, died. While most patients
were admitted to a regular ward, the percentage of patients
admitted to a MCU/ICU increased through the risk cat-
egories in both scores to 12.6 and 11.9 % in the high risk
category of abbMEDS and CURB-65, respectively.
Discussion
This study investigated the value of abbMEDS and CURB-
65 in internal medicine patients presenting with sepsis at
the ED. We found a moderate predictive value regarding
28-day mortality of both the abbMEDS (AUC 0.77) and
CURB-65 (AUC 0.73). In addition, both scores were feas-
ible at our ED with complete scores in 92.7 and 93.9 %,
respectively. New findings are that the abbMEDS
categorizes patients well with respect to two important
clinical decisions, namely empirical antibiotic treatment
(e.g. narrow or broad-spectrum) and clinical disposition
(i.e. whether a patient is admitted to the hospital and to
what level of care), and that the abbMEDS performs
better than the CURB-65.
With regard to the discriminatory value of the Abb-
MEDS, we found a slightly lower AUC than in the deriv-
ation study (AUC 0.77 vs. 0.82) by Vorwerk et al. [9],
which may result from a difference in patient selection.
The abbMEDS was well calibrated in our population, but
compared to the derivation study, we found a higher mor-
tality in the low risk category (3.6 vs. 1.6 %). An explan-
ation for this finding may be that, due to the prominent
role of the general practitioner in the Netherlands, the
patients who are referred to the hospital and then assigned
to the low risk category are sicker than patients in other
countries [11, 16]. The CURB-65 was developed for
patients with CAP [5]. Later, the CURB-65 was validated
in an ED population with an infection [6]. In that study, a
higher AUC (0.79) was found than in ours (0.73), which
might be explained by the higher mortality in our study
population (13.0 vs. 3.9 %). The mortality in our study was
higher because we selected patients with sepsis instead of
patients with infection.
The first new finding of our study is that the abbMEDS
matches two current clinical decisions in the management
of sepsis patients, namely empirical antibiotic treatment
and clinical disposition. This is less the case for the CURB-
65. In the low risk categories of both scores, roughly 30 %
did not receive antibiotics or were treated with oral antibi-
otics (i.e. treatment that would not require admission to
the hospital). The most severely ill patients in the high risk
categories received almost exclusively IV broad-spectrum
antibiotics. This is where the abbMEDS matches current
clinical decisions better than the CURB-65, for all high risk
abbMEDS patients were treated with IV broad-spectrum
Table 2 Mortality within 28 days per abbMEDS risk category
compared to the derivation study (10)
Risk category 28-day mortality, n (%)
Current study Derivation study (10)
Mortality Patients Mortality Patients
Low risk 12 (3.6) 331 1 (1.6) 63
Intermediate risk 59 (19.5) 302 48 (23.4) 205
High risk 18 (46.2) 39 23 (59.0) 39
Total 89 (13.2) 672 72 (23.5) 307
Fig. 2 Number of patients and 28-day mortality for the three risk categories of abbMEDS and CURB-65
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antibiotics, in contrast to 9.4 % of the high risk CURB-65
patients who were treated with no or oral antibiotics. We
did not find significant differences in mortality between
these different treatment groups. However, our mortality
figures are too small to draw conclusions on this matter.
We additionally analyzed adequacy of our empirical
treatment (antibiotics started at the ED) based on in
vitro susceptibility. We found that adequacy was
related to the abbMEDS risk categories. With increas-
ing risk category of the abbMEDS, more patients were
treated with adequate antibiotics. However, this was
not the case for CURB-65, as 15.9 % of the patients in
the high risk category received inadequate treatment.
The need for high adequacy is most urgent in the high
risk category with the most severely ill patients [17].
For the less severely ill patients, a lower adequacy can be
accepted, as confining microbial resistance to antibiotics is
more important in this large group of patients.
The second new finding regarding clinical decisions was
that the abbMEDS matches current management regard-
ing clinical disposition. Again, the CURB-65 did this less
well. With increasing risk category of the abbMEDS, more
patients were admitted to the MCU/ICU, while the frac-
tion of patients who were not admitted to the hospital
decreased. In contrast, in the high risk category of the
CURB-65, 4 (2.5 %) patients were not admitted.
To our knowledge, we showed for the first time that
the abbMEDS matches current clinical decisions re-
garding empirical antibiotic treatment and clinical dis-
position of sepsis patients at the ED. In patients with
CAP, the CURB-65 is already used to provide clinical
decision support. This resulted in more standardized
care and reduced the use of broad-spectrum antibi-
otics, while patient safety was maintained [18, 19]. We
think that the abbMEDS has the potential to provide
clinical decision support in patients presenting with
Table 3 Antibiotic treatment and 28-day mortality per risk category of the abbMEDS and CURB-65
n (%) Low risk Intermediate risk High risk
Patients Mortality Patients Mortality Patients Mortality
AbbMEDS
No antibiotics 52 (15.7) 1 (1.9) 20 (6.6) 4 (20.0) 0 0
Oral 41 (12.4) 0 21 (7.0) 3 (14.3) 0 0
IV narrow-spectrum 22 (6.6) 0 10 (3.3) 1 (10.0) 0 0
IV broad-spectrum 216 (65.3) 11 (5.1) 251 (83.1) 51 (20.3) 39 (100.0) 18 (46.2)
Total (672)# 331 (49.3) 12 (3.6) 302 (44.9) 59 (19.5) 39 (5.8) 18 (46.2)
CURB-65
No antibiotics 54 (15.7) 3 (5.6) 10 (5.6) 0 7 (4.4) 1 (14.3)
Oral 47 (13.7) 3 (6.4) 13 (7.3) 1 (7.7) 4 (2.5) 0
IV narrow-spectrum 24 (7.0) 0 5 (2.8) 0 4 (2.5) 0
IV broad-spectrum 219 (63.7) 14 (6.4) 150 (84.3) 23 (15.3) 144 (90.6) 41 (28.5)
Total (681)# 344 (50.5) 20 (5.8) 178 (26.1) 24 (13.5) 159 (23.3) 42 (26.4)
#The totals are depicted to show how many data were available for all patients
There were no significant differences in mortality per treatment class within each risk category
Table 4 Adequacy of antibiotic treatment and 28-day mortality per risk category of the abbMEDS and CURB-65
n (%) Low risk Intermediate risk High risk
Patients Mortality Patients Mortality Patients Mortality
AbbMEDS
Adequate* 60 (65.9) 1 (1.7) 80 (80.8) 13 (16.3) 13 (92.9) 6 (46.2)
Inadequate 31 (34.1) 1 (3.2) 19 (19.2) 5 (26.3) 1 (7.1) 1 (100)
Total (204)# 91 (44.6) 2 (2.2) 99 (48.5) 18 (18.2) 14 (6.9) 7 (50.0)
CURB-65
Adequate 61 (70.1) 4 (6.6) 43 (70.5) 3 (7.0) 58 (84.1) 15 (25.9)
Inadequate 26 (29.9) 1 (3.8) 18 (29.5) 5 (27.8) 11 (15.9) 1 (9.1)
Total (217)# 87 (40.1) 5 (5.7) 61 (29.5) 8 (13.1) 69 (31.8) 16 (23.2)
#The totals are depicted to show how many data were available for all patients
*p = 0.04 for trend. Adequacy was defined as in vitro susceptibility of the identified microorganisms for the empirical treatment
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sepsis. However, future studies are needed and these
should confirm that the abbMEDS can indeed appro-
priately and safely be used to provide this support on
clinical decisions. The abbMEDS could then develop
from a risk stratification score into a clinical decision sup-
port tool with the potential to increase the standard of
care in sepsis patients. Hopefully, this will yield improved
survival, reduced use of broad-spectrum antibiotics and
reduced healthcare costs in sepsis patients.
This study has some limitations. First, we cannot ex-
clude the risk of misclassification of measurements or
data. However, we used standardized extraction forms
and the main factors studied (laboratory values, anti-
biotic treatment, clinical disposition and mortality) are
less likely to be subject of misclassification. Second,
our study was limited to one hospital, but we included
over 700 patients in a 15-month study period. Third,
current clinical decisions might not be optimal as they
are physician-dependent. However, our study reflects
clinical practice and it is improbable that our manage-
ment is less optimal than in other hospitals. A way to
examine adequate management in a better way is to ask a
panel of experts whether they agree with the management
decisions based on the calculated score in selected cases.
Considering the limitations, our study must be seen as an
exploratory one. To our opinion, the results justify a pro-
spective study that implements such a panel.
Conclusions
Both the abbMEDS and CURB-65 are good predictors of
28-day mortality in sepsis patients and are very feasible at
the ED. The abbMEDS is well calibrated. A new finding is
that the abbMEDS matches current clinical decisions in
sepsis patients concerning antibiotic treatment and clinical
disposition well, while this is less the case for the CURB-65.
To improve the standard of care of sepsis, further research
on the ability of the abbMEDS to provide support in clinical
decisions in sepsis patients at the ED must be performed.
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Total (681)# 344 (50.5) 20 (5.8) 178 (26.1) 24 (13.5) 159 (23.3) 43 (27.0)
# The totals are depicted to show how many data were available for all patients
There were no significant differences in mortality per disposition group within each risk category
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